GPT and metabolic dysfunction-associated steatotic liver disease: In summary, treatment with CHLZT or AICAR decreased the serum levels of TG, TC, LDL-C, AST, ALT, and insulin in NAFLD rats, and significantly increased their serum HDL-C levels, suggesting that CHLZT and AICAR can serve to protect NAFLD rats.